Advertisement
Screener

VERACYTE, INC. (VCYT) Overview

VERACYTE, INC. (VCYT) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.31; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 0.35; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.24; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.01; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$28.51$33.46$39.28$46.10$54.11$63.512025-09-292026-09-29$14.54$19.53$26.23$35.22$47.30$63.512021-09-292026-09-29$5.12$8.99$15.79$27.72$48.67$85.452016-09-292026-09-29$4.28$7.80$14.18$25.81$46.96$85.452013-10-302026-09-29$4.28$7.80$14.18$25.81$46.96$85.452013-10-302026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$46.08
Previous close
$45.23
Change
$0.85
Change (%)
1.88%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

VCYT
+9.45%
S&P 500
(m)

1 year

VCYT
+37.10%
S&P 500
(m)

3 years

VCYT
+106.36%
S&P 500
(m)

5 years

VCYT
+1.86%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 0.31

-0.090.070.220.380.5331 Mar 2025: estimate (m); actual 0.0931 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.0130 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.2430 Sept 2025(m)31 Mar 2026: estimate (m); actual 0.3531 Mar 2026(m)30 Jun 2026: estimate (m); actual 0.3130 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)0.31(m)(m)
1 Jan 202631 Mar 2026(m)0.35(m)(m)
1 Jul 202530 Sept 2025(m)0.24(m)(m)
1 Apr 202530 Jun 2025(m)-0.01(m)(m)
1 Jan 202531 Mar 2025(m)0.09(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 0.82

-1.19-0.64-0.090.451.0031 Dec 2021: estimate (m); actual -1.1131 Dec 2021(m)31 Dec 2022: estimate (m); actual -0.5131 Dec 2022(m)31 Dec 2023: estimate (m); actual -1.0231 Dec 2023(m)31 Dec 2024: estimate (m); actual 0.3131 Dec 2024(m)31 Dec 2025: estimate (m); actual 0.8231 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)0.82(m)(m)
1 Jan 202431 Dec 2024(m)0.31(m)(m)
1 Jan 202331 Dec 2023(m)-1.02(m)(m)
1 Jan 202231 Dec 2022(m)-0.51(m)(m)
1 Jan 202131 Dec 2021(m)-1.11(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 150.32M ■ Earnings 25.49M — Profit margin 16.96%

-18.04M13.5%44.09M19.1%106.23M24.7%168.36M30.3%30 Sept 2025: revenue 131.87M; earnings 19.14M; profit margin 14.51%30 Sept 202531 Dec 2025: revenue 140.64M*; earnings 41.20M*; profit margin 29.29%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 139.07M; earnings 28.71M; profit margin 20.64%31 Mar 202630 Jun 2026: revenue 150.32M; earnings 25.49M; profit margin 16.96%30 Jun 2026

31 Dec 2025 ■ Revenue 517.14M ■ Earnings 66.40M — Profit margin 12.84%

-145.39M-21.6%99.12M-9.8%343.63M2.0%588.13M13.8%31 Dec 2022: revenue 296.54M; earnings -36.60M; profit margin -12.34%31 Dec 202231 Dec 2023: revenue 361.05M; earnings -74.40M; profit margin -20.61%31 Dec 202331 Dec 2024: revenue 445.76M; earnings 24.10M; profit margin 5.41%31 Dec 202431 Dec 2025: revenue 517.14M; earnings 66.40M; profit margin 12.84%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$46.08(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$46.08High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning VCYT

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$114.53M
Profit margin
20.38%
Return on assets · 12 month
8.09%
Index membership
(m)
Employees
755.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.45M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
6.27%*
Total return · month
6.32%*
Total return · quarter
-23.44%*
Total return · half year
53.55%*
Total return · year to date
9.45%*
Total return · 1 year
37.10%*
Total return · 3 years
106.36%*
Total return · 5 years
1.86%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$561.90M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

VERACYTE, INC. Overview

View more →

(m)

(m)

SEC CIK
1384101
Industry (SIC)
8071 Services-Medical Laboratories
Country of operation
United States
Business address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, California, 94080, United States
Fiscal year end
1231
Phone
(650) 243-6300

Similar stocks

Stock NameCountryMarket CapPE Ratio
Celcuity Inc. (CELC)United States$3.887B-22.62
CareDx, Inc. (CDNA)United States$3.174B13.21
GRAIL, Inc. (GRAL)United States$5.591B-7.78
RadNet, Inc. (RDNT)United States$5.611B-229.65
Fortrea Holdings Inc. (FTRE)United States$1.903B-19.43
Personalis, Inc. (PSNL)United States$1.769B-13.30
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
BIODESIX INC (BDSX)United States$0.312B